Researchers identify colistin-resistant bacteria in Brazilian rivers
A study of samples from two Brazilian rivers found a high incidence of colistin-resistant bacteria and MCR-1 producers, Brazilian and Portuguese researchers reported today in the Journal of Global Antimicrobial Resistance.
The analysis of eight water samples taken along the course of the Sapucai and Sapucaizinho rivers in Sao Paulo found 11 strains of bacteria (8 Escherichia coli, 2 Klebsiella pneumoniae, and 1 K quasipneumoniae) that were resistant to colistin, a last-resort antibiotic for multidrug-resistant (MDR) infections. Whole-genome sequencing revealed that six of the strains were positive for the MCR-1 gene, with four carrying MCR-1.1 and two carrying MCR-1.26. All of the E coli strains and one of the K pneumoniae strains were MDR and carried numerous antimicrobial-resistance mechanisms.
The analysis also identified several E coli sequence types, including the high-risk clones ST10 and ST131-H22, which have been found to cause infections in humans and animals, and revealed that the MCR-1 genes were detected in highly similar IncX4 plasmids—the mobile pieces of DNA that have been associated with the global dissemination of MCR-1 genes in humans and food-producing animals.
The study authors say the findings likely reflect anthropogenic activities nearby and that the presence of high-risk MDR E coli clones at the human-animal-environment interface is of concern because of the risk of human exposure.
Jun 6 J Glob Antimicrob Resist study
FDA approves GSK's measles, mumps, rubella vaccine
Pharmaceutical company GSK today announced that the US Food and Drug Administration (FDA) has approved its measles, mumps, and rubella (MMR) vaccine—called Priorix—for people ages 12 months or older, which adds an MMR vaccine from a second company to the US market.
Priorix has already been licensed in 100 countries, with 800 million doses distributed so far, GSK said in a statement. Currently, Merck makes two MMR vaccines for the US market: one targeted to just MMR and another that is designed to also protect against chickenpox (varicella).
Temi Folaranmi, MD, GSK's vice president of therapeutics for US medical affairs, said measles outbreaks in recent years show how quickly diseases can return. "Missed vaccinations during the pandemic makes children even more vulnerable to vaccine-preventable diseases like measles," he said, adding that having Priorix available in the United States will give healthcare providers more than one option as they work toward getting kids caught up on their vaccines.
The vaccine is given in two doses and can be also administered as a second dose in people who have received a first dose of a different MMR vaccine. The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to consider including Priorix in a June discussion about vaccine schedules and recommendations.
Jun 6 GSK statement